Acquisition and Disposition -Additional Information (Details) $ / shares in Units, $ in Thousands		3 Months Ended
	Sep. 08, 2023 USD ($) item $ / shares shares	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 01, 2024 USD ($)	Dec. 31, 2023 USD ($)
Surface Acquisition
Cash consideration				$ 170,000
Additional consideration				17,800
Pretax profit (loss)		$ 102,875	$ (75,729)
Income under TSA		300
TSA receivables, net (Note 6)		32,194
TSA payables and other accrued liabilities		30,770
Goodwill					$ 943
Net impairment charge		6,772
Finite-lived assets, net of accumulated amortization of $812 and $639, as of March 31, 2024 and December 31, 2023, respectively		28,245			41,871
Contingent consideration, current					$ 3,300
Out-license - Novartis Institutes
Surface Acquisition
Impairment charge		10,600
CIMERLI Ophthalmology Franchise [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Surface Acquisition
Cash consideration		187,800		170,000
Additional consideration				$ 17,800
Gain on sale transaction		153,600
Retention bonus		11,100
Pretax profit (loss)		7,400	$ (3,900)
Acquisition related costs		7,200
Surface Acquisition
Surface Acquisition
Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares	0.1960
Share price | $ / shares	$ 5.2831
Contingent value right per share | item	1
Contingent value rights payment period	10 years
Goodwill	$ 0
Business Combination, Number of Out Licensed Partnership Program | item	2
Fair value of the contingent consideration		3,800
Contingent consideration, current		0
Surface Acquisition | Out-license - Novartis Institutes
Surface Acquisition
Net impairment charge		$ 6,800
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]		Selling General And Administrative Expense
Impairment charge		$ 10,600
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]		Selling General And Administrative Expense
Surface Acquisition | Surface GSK Agreement
Surface Acquisition
Milestone and royalty based CVR payments (as percent)	70.00%
Surface Acquisition | Surface's SRF114 proprietary drug product candidate
Surface Acquisition
Upfront payment based CVR payments (as percent)	25.00%
Surface Acquisition | Surface's SRF388 proprietary drug product candidate
Surface Acquisition
Upfront payment based CVR payments (as percent)	50.00%